sci_record · open
Corpus Engine
pmid:35027921version sci 1.2 revision 5 · sha256 sha256:a63979991c40bb01ef19a7869b34502e4d8f9e3fed4e292fd11e80009e6e6c51
No scientific verdict has been recorded. Explore the available material or start a research fork.
BACKGROUND: Mounting evidence has confirmed that peroxisome proliferator-activated receptors (PPARs) played a crucial role in the development and progression of bladder cancer (BLCA). The purpose of this study is to comprehensively investigate the function and prognostic value of PPAR-targeted genes in BLCA. METHODS: The RNA sequencing data and clinical information of BLCA patients were acquired from The Cancer Genome Atlas (TCGA). The differentially expressed PPAR-targeted genes were investigated. Cox analysis and least absolute shrinkage and selection operator (LASSO) analysis were performed for screening prognostic PPAR-targeted genes and constructing the prognostic PPAR signature and then validated by GSE13507 cohort and GSE32894 cohort. A nomogram was constructed to predict the outcomes of BLCA patients in combination with PPAR signature and clinical factors. Gene set enrichment analysis (GSEA) and immune cell infiltration were implemented to explore the molecular characteristics of the signature. The Genomics of Drug Sensitivity in Cancer (GDSC) database was used to predict the chemotherapy responses of the prognostic signature. The candidate small molecule drugs targeting PPAR-targeted genes were screened by the CMAP database. RESULTS: We constructed and validated the prognostic signature comprising of 4 PPAR-targeted genes (CPT1B, CALR, AHNAK, and FADS2), which was an independent prognostic biomarker in BLCA patients. A nomogram based on the signature and clinical factors was established in the TCGA set, and the calibration plots displayed the excellent predictive capacity. GSEA analysis indicated that PPAR signature was implicated in multiple oncogenic signaling pathways and correlated with tumor immune cell infiltration. Patients in the high-risk groups showed greater sensitivity to chemotherapy than those in the low-risk groups. Moreover, 11 candidate small molecule drugs were identified for the treatment of BLCA. CONCLUSION: We constructed and validated a novel PPAR signature, which showed the excellent performance in predicting prognosis and chemotherapy sensitivity of BLCA patients.
Ke Zhu, Wen Deng, Hui Deng, Xiaoqiang Liu, Gongxian Wang, Bin Fu
sci_record · open
version sci 1.2 revision 5 · sha256 sha256:a63979991c40bb01ef19a7869b34502e4d8f9e3fed4e292fd11e80009e6e6c51
source_text · open
· sha256 sha256:f1e8304409af54fe6b77d8fd396b580be30fd90f552482c87825643fd1b29016
Start a research fork to check a result or build on this work. Choose the result you want to reproduce after signing in.
Sign in to start a forkScientific verdict — what the evidence supports
No scientific verdict
Nothing has been adjudicated on the evidence yet. An editorial decision may still close this record, and that is not a result.
Editorial disposition — what the desk does with it
No disposition
The desk has recorded no decision on this submission.
No automated assessment is available.
no language-model credential is configured, so no machine critique can be produced
No verified model response is available for publication.
No researcher commentary has been recorded yet.
This submission carries no registered claim, so no comparison plan exists. The engine refuses to compute a verdict without one.
| Order | Condition | State | Attempts | Accepted | Observations |
|---|---|---|---|---|---|
| No execution order has been registered for this submission. | |||||
| Seq | Event | Actor | Recorded | Event hash |
|---|---|---|---|---|
| 5180 | submission.received | admin+journal-prd@bntrg.co.uk intake_service | 2026-11-04T07:06:16.403999Z | c5f9c3aaa792c99fa1d94fa9… |
| 5181 | paper.sci_version_held | corpus_engine external_service | 2026-11-04T07:06:16.413898Z | 90a39f65d4857f7c9a70824f… |